Tom Costas's questions to XBiotech (XBIT) leadership • Q2 2016
Question
Tom Costas, a private investor, asked about a critical review from an individual at the European Society of Medical Oncology (ESMO) regarding the company's Phase 3 study and questioned its potential impact on the European medical community's adoption of Xilonix upon approval.
Answer
Founder, President & CEO John Simard dismissed the review as not credible, highlighting the reviewer's undisclosed affiliation as a spokesperson for Regorafenib, a competitor drug. Simard stated that the company saw no new insights in the analysis and could not speculate on how one individual's opinion might influence the broader medical community.